Kenneth Simon's Contact Details

Kenneth Simon's Company Details

Revitope

Cambridge, MA, US • 20 - 49 Employees
BioTech/Drugs

Revitope is an early stage biotechnology company focused on developing the next-generation of T cell redirecting biologics. Immune-based therapies are redefining how cancer is treated as clinical studies demonstrate unprecedented deep and durable responses in multiple cancers. In particular redirecting T cells to tumors is a successful strategy for immunotherapy of liquid tumors. However, unleashing a potent immune response that is entirely focused on the tumor continues to be elusive.Revitope is developing a new class of biologic prodrugs we call Programmable Antibody Circuits or PACs that are engineered to focus immune activation to the cancer cell surface while expanding the antigenic targeting space.